PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/86, 7/01 — A1

(11) International Publication Number: **WO 98/27216**

(43) International Publication Date: 25 June 1998 (25.06.98)

(21) International Application Number: PCT/GB97/03438

(22) International Filing Date: 12 December 1997 (12.12.97)

(30) Priority Data:
9626029.4 14 December 1996 (14.12.96) GB

(71) Applicant *(for all designated States except US)*: THE UNIVERSITY OF LEEDS [GB/GB]; Research Support Unit, Leeds LS2 9JT (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MARKHAM, Alexander, Fred [GB/GB]; The University of Leeds, West Riding Medical Research Unit, Molecular Medicine, Clinical Sciences Building, St. James University Building, Leeds LS9 7TF (GB). MEREDITH, David, Mark [GB/GB]; The University of Leeds, West Riding Medical Research Unit, Molecular Medicine, Clinical Sciences Building, St. James University Building, Leeds LS9 7TF (GB).

(74) Agent: MARKGRAAF PATENTS; The Crescent, 54 Blosom Street, York YO2 2AP (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.
Date of receipt by the International Bureau:
09 February 1998 (09.02.1998)

(54) Title: EHV-1 VECTORS

(57) Abstract

The invention relates to manipulation of equine herpes virus for use in gene therapy and in particular to modifications of the virus so that it can carry heterologous material and furthermore, preferably, be replication deficient so that the virus cannot replicate in the target tissue.